Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Travere Therapeutics, Inc. (TVTX) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Travere Therapeutics, Inc. (TVTX) lobbying for?
Summary of Lobbying Data:
Company: Travere Therapeutics, Inc.
Lobbying Firms: The Health Equity Strategies Group, Cornerstone Government Affairs, Travere Therapeutics, Inc., 2359 Strategies, Llc, Alston & Bird Llp
General Issues Lobbied On: Taxation/Internal Revenue Code, Medical/Disease Research/Clinical Labs, Pharmacy, Health Issues, Medicare/Medicaid, Copyright/Patent/Trademark, Budget/Appropriations
Specific Issues Lobbied On: Reducing incentives for clinical testing to develop biopharmaceuticals for individuals suffering from rare/orphan diseases, tax treatment of net operating losses, FY 2022 and FY 2023 CDC Appropriations for state newborn screening technical assistance, rare kidney disease, the Orphan Drug Tax Credit, drug policies and access to therapies for patients with rare diseases, expedited FDA pathways, reimbursement, and detection.
Government Agencies Lobbied: Senate, Centers For Medicare and Medicaid Services (CMS), Department of Health & Human Services (HHS), House of Representatives.
One could infer that Travere Therapeutics, Inc. is lobbying on various issues related to rare/orphan diseases because the company specializes in developing innovative therapies for patients with rare diseases. Based on the specific issues they lobbied on, it can also be inferred that the company is advocating for favorable tax treatment and incentives to encourage research and development in the rare disease space, as well as increased funding for state newborn screening programs and expedited FDA pathways for therapies targeting rare diseases. Additionally, the company appears to be focused on issues related to Medicare/Medicaid and drug pricing/reimbursement, which could be related to the company’s efforts to increase access to their rare disease therapies for patients in need.
